Public Defence: Henriette Jodal Henriette Cecilie Jodal at Institute of Health and Society will be defending the thesis “The risk of colorectal cancer incidence and mortality after screening and adenoma removal” for the degree of PhD (Philosophiae Doctor).

Image may contain: Smile, Neck, Sleeve, Gesture, Happy.

Photo: Anita Aalby.

An electronic copy of the thesis may be ordered from the faculty up to 2 days prior to the public defence. Inquiries regarding the thesis after the public defence must be addressed to the candidate.

Trial Lecture – time and place

See Trial Lecture.

Adjudication committee

  • First opponent: Professor and Executive Director Jason A. Dominitz, University of Washington, Veterans Health Administration
  • Second opponent: Professor Fang Fang, Karolinska Instiutet
  • Third member and chair of the evaluation committee: Associate Professor Sheraz Yaqub, University of Oslo

Chair of the Defence

Associate Professor Marte Lie Høivik, Faculty of Medicine, University of Oslo

Principal Supervisor

Associate professor Magnus Løberg, University of Oslo


Colorectal cancer is a major health burden worldwide. Screening for colorectal cancers and surveillance programmes after adenoma removal have been implemented in many countries to decrease the risk of colorectal cancer incidence and mortality. This thesis aims to investigate the effect of colorectal cancer screening and adenoma removal on colorectal cancer incidence and mortality, as well as the risk of colorectal cancer death from an interval cancer occurring between two screening episodes.

The thesis includes a systematic review and meta-analysis of existing randomised controlled trials on colorectal cancer screening, a subanalysis of a randomised controlled trial on colorectal cancer screening (the NORCCAP study), as well as a cohort study of 40,000 Norwegian individuals 40 years or older who have had an adenoma removed.

Colorectal cancer screening with guaiac faecal occult blood test and sigmoidoscopy had a long-lasting effect on colorectal cancer mortality of at least 15 years. Individuals who experienced an interval cancer after a negative screening exam had similar prognosis to clinically detected cancers. Both sigmoidoscopy screening and adenoma removal had less effect in women than in men, thus sex-specific guidelines should be considered.

Additional information

Contact the research support staff.

Published Apr. 21, 2022 3:59 PM - Last modified May 3, 2022 10:35 AM